Boston Scientific Corporation Stock price
Equities
BSX
US1011371077
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
56.14 USD | +0.45% | +0.92% | +21.33% |
Nov. 27 | Global markets live: Novo Nordisk, HSBC, Amazon, Tesla, Huawei... | ![]() |
Nov. 27 | Canaccord Genuity Adjusts Price Target on Boston Scientific to $64 From $60, Maintains Buy Rating | MT |
Financials (USD)
Sales 2023 * | 14.11 B | Sales 2024 * | 15.30 B | Capitalization | 82.24 B |
---|---|---|---|---|---|
Net income 2023 * | 1,528 M | Net income 2024 * | 2,082 M | EV / Sales 2023 * | 6,31x |
Net Debt 2023 * | 6,787 M | Net Debt 2024 * | 4,455 M | EV / Sales 2024 * | 5,67x |
P/E ratio 2023 * | 53,7x | P/E ratio 2024 * | 38,2x | Employees | 45,000 |
Yield 2023 * | - | Yield 2024 * | - | Free-Float | 84.57% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
1 day | +0.45% | ||
1 week | +0.92% | ||
Current month | +0.45% | ||
1 month | +6.89% | ||
3 months | +4.70% | ||
6 months | +8.34% | ||
Current year | +21.33% |
1 week
54.91
56.22

1 month
50.84
56.22

Current year
44.35
56.22

1 year
44.35
56.22

3 years
33.42
56.22

5 years
24.10
56.22

10 years
11.10
56.22

Managers | Title | Age | Since |
---|---|---|---|
Michael Mahoney
CEO | Chief Executive Officer | 58 | 2011 |
Daniel Brennan
DFI | Director of Finance/CFO | 57 | 1995 |
Jodi Eddy
CTO | Chief Tech/Sci/R&D Officer | 50 | 2015 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Wichmann
BRD | Director/Board Member | 60 | 2021 |
Director/Board Member | 68 | 2015 | |
Edward Ludwig
BRD | Director/Board Member | 71 | 2014 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
9.23% | 1 M€ | -13.95% | ||
6.04% | 131 M€ | -2.21% | ||
5.66% | 89 M€ | -3.57% | - | |
5.40% | 48 M€ | -4.26% | - | |
4.90% | 820 M€ | -4.74% | - |
Date | Price | Change | Volume |
---|---|---|---|
23-12-01 | 56.14 | +0.45% | 4,730,456 |
23-11-30 | 55.89 | +0.81% | 8,346,178 |
23-11-29 | 55.44 | +0.93% | 4,780,411 |
23-11-28 | 54.93 | -1.36% | 6,450,749 |
23-11-27 | 55.69 | +0.11% | 5,313,739 |
Delayed Quote Nyse, December 01, 2023 at 04:00 pm EST
More quotes
Boston Scientific Corporation specializes in the design, manufacturing and marketing of medical equipment and materials. Net sales break down by area of application as follows:
- cardiovascular (61.5%): products used in cardiology surgeries (28.4% of net sales), cardiac rhythm management (26.8%), peripheral surgeries (24.2%), electrophysiology tests (7.5%) and other (13.1%);
- endodontic surgery (31.3%): equipment used in endoscopy (55.6% of net sales) and urology (44.4%);
- neuromodulation (7.2%).
The United States account for 60.2% of net sales.
Calendar
2024-01-30
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
A-
Sell
Buy

Mean consensus
BUY
Number of Analysts
32
Last Close Price
56.14USD
Average target price
60.12USD
Spread / Average Target
+7.08%
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.33% | 82 244 M $ | |
-9.91% | 192 B $ | |
-15.80% | 165 B $ | |
+18.83% | 111 B $ | |
+13.76% | 64 424 M $ | |
-8.19% | 49 148 M $ | |
-8.38% | 41 460 M $ | |
-13.94% | 37 623 M $ | |
+18.89% | 31 598 M $ | |
-23.30% | 23 482 M $ |